Cholestech's lipid and liver function test launched in the US:
This article was originally published in Clinica
Hayward, California-based Cholestech is rolling out its Lipid Profile ALT test cassette in the US after the FDA granted CLIA waived status for the product, a test for liver function. The device enables healthcare providers to test a patient's lipid profile and alanine aminotransferase (ALT) levels simultaneously, giving results within five minutes. ALT is the most common marker for liver damage. The test can be performed in the doctor's office lab with just a single fingerstick. It is designed to allow doctors to monitor the patient's use of certain drugs, particularly statins, though lipid and liver monitoring are recommended when using a variety of other prescription drugs. Tests are performed before treatment initiation to establish a baseline level and periodically thereafter to help determine the appropriate therapeutic course of action.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.